1. At a Glance – ICU-Level Growth, OPD-Level Valuation
A ₹873 crore market cap hospital chain with just ₹40.24 crore FY25 revenue and ₹9.41 crore PAT? Welcome to Gujarat Kidney & Super Speciality Ltd — currently trading at ₹111 with a spicy P/E of 88.7 and ROCE of 51.5%.
Latest quarter (Dec 2025) sales came in at ₹23.25 crore — up 97.2% YoY. PAT stood at ₹3.70 crore — up 17.6% YoY. OPM? A juicy 29.68% this quarter and 41.15% at FY25 level.
Debt? Just ₹8.31 crore.
Debt-to-equity? 0.32.
Promoter holding? 71.45%.
IPO size? ₹250.8 crore in December 2025.
A regional hospital chain with 539 beds, 80 ICU beds, robotics plans, multiple acquisitions, and an acquisition spree right after IPO.
The real question: Is this Gujarat’s next hospital giant in the making… or just a fast-growing acquisition machine running on IPO oxygen?
Let’s scrub in.
2. Introduction – From Kidney Specialist to Serial Acquirer
Incorporated in 2019, Gujarat Kidney & Super Speciality Ltd is basically the ambitious younger cousin in the hospital industry who didn’t build slowly — it went straight for acquisitions.
This is not a 40-year-old legacy hospital brand.
This is a 6-year-old chain that:
- Operates 7 hospitals + 1 pharmacy
- Has 539 total beds (389 operational)
- Runs 80 ICU beds
- Focuses heavily on renal sciences
And then decided:
“Why grow organically when you can just acquire everyone?”
IPO in December 2025.
Within weeks:
- Approved 100% acquisition of Parekhs Hospital for ₹77 crore
- Approved 100% acquisition of Ashwini for ₹14 crore
- Approved 49% of Harmony for ₹10.78 crore
- Approved 51% Patel Pharmacy + Patel Multispeciality
This isn’t slow healthcare expansion.
This is hospital Pokémon — gotta catch ‘em all.
But here’s the interesting part — they are not burning cash recklessly.
FY25:
- Revenue: ₹40.24 crore
- PAT: ₹9.50 crore
- OPM: 41.15%
- ROE: 51.2%
For a hospital business, these are not normal numbers.
But are they sustainable?
3. Business Model – WTF Do They
